Abstract
Abstract 4000: The significance of GLP-1R and its agonist in neuroendocrine neoplasms
Cancer research (Chicago, Ill.), Vol.85(8_Supplement_1), pp.4000-4000
04/21/2025
DOI: 10.1158/1538-7445.AM2025-4000
Abstract
Neuroendocrine neoplasms (NENs) are rare cancers originating from neuroendocrine cells that are found throughout the body. NENs are subdivided into 2 categories: Well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Both NET and NEC are highly metastatic and difficult to treat. NEN cases are on the rise and yet the etiology remains unclear. Commonly used drugs such as proton pump inhibitors can promote NET growth and result in poor prognosis for NET patients. Nowadays, the diabetes and weight loss drug semaglutide, a glucagon-like peptide 1 receptor (GLP-1R) agonist, has gain extensive popularity and are currently being taken by over 15 million people in the USA. Semaglutide is contraindicated for NET patients with medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) since some of these cancers express the GLP-1R. However, this area of research remains understudied. Little is known about the expression levels of GLP-1R in NEN from different anatomical locations and their response to semaglutide since these are rare cancers and few NET models are available for drug testing. We recently identified 2 human NET cell lines (GOT1 and NT-3) that express the GLP-1R and showed that semaglutide promotes tumor cell growth both in vitro and in vivo. In this study, we aim to investigate the levels of GLP-1R expression in a large collection of NEN tissue microarrays and determine the effects of semaglutide in novel GLP-1R positive NET patient-derived spheroid cultures. We stained for GLP-1R expression by immunohistochemistry in 357 NET tissue microarrays covering 7 classes of NEN: 78 pancreas NET, 62 duodenum NET, 33 ileal NET, 42 lung NET, 10 small cell lung NEC, 12 extrapulmonary visceral NEC, 29 thyroid NET, 12 gastric NET, 6 appendix NET, 6 rectum NET, 22 pheochromocytoma, 22 paraganglioma, and 23 Merkel cell carcinoma. Furthermore, we generated GLP-1R positive pancreas, ileal, and duodenal NET spheroids for drug testing. Our data showed 45% of duodenum NET, 17% of gastric NET, and 14% of pancreas NET stained positive for GLP-1R expression. Less than 2% of other classes NET or NEC stained positive for GLP-1R expression. Using newly established NET patient-derived spheroid models, we demonstrated that 100 nM of semaglutide accelerates tumor cell growth by 1.4 to 2-fold. Surprisingly, duodenum NET is the class of NET that frequently express GLP-1R and should be highly cautioned for the semaglutide usage.
Details
- Title: Subtitle
- Abstract 4000: The significance of GLP-1R and its agonist in neuroendocrine neoplasms
- Creators
- Sophia A. Hueser - University of IowaReese E. Townsend - University of IowaCasandro J. Chan - University of IowaLeona Rupp - University of IowaLeopaul J. Chan - University of IowaDawn E. Quelle - University of IowaJoseph S. Dillon - University of IowaAndrew M. Bellizzi - University of IowaJames R. Howe - University of IowaPo Hien H. Ear - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Cancer research (Chicago, Ill.), Vol.85(8_Supplement_1), pp.4000-4000
- Publisher
- AMER ASSOC CANCER RESEARCH
- DOI
- 10.1158/1538-7445.AM2025-4000
- ISSN
- 0008-5472
- eISSN
- 1538-7445
- Language
- English
- Date published
- 04/21/2025
- Academic Unit
- Pathology; Surgery; Fraternal Order of Eagles Diabetes Research Center; Neuroscience and Pharmacology; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984813166002771
Metrics
16 Record Views